众兴菌业(002772) - 2024 Q3 - 季度财报

Financial Performance - Revenue for Q3 2024 reached ¥501,799,781.20, an increase of 15.72% compared to the same period last year[4] - Net profit attributable to shareholders was ¥59,171,836.29, a significant increase of 369.59% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥45,011,245.48, up 234.99% from the previous year[4] - Total operating revenue for the current period is CNY 1,416,478,603.36, a decrease of 2.5% compared to CNY 1,452,471,968.84 in the previous period[17] - Net profit for the current period is CNY 87,553,243.07, down from CNY 175,870,381.99, indicating a decline of about 50.3%[19] - Basic and diluted earnings per share for Q3 2024 were both 0.2254 CNY, down from 0.4467 CNY year-over-year[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,308,910,734.88, reflecting a growth of 3.87% from the end of the previous year[4] - Total assets increased to CNY 6,308,910,734.88 from CNY 6,073,765,300.40, representing a growth of approximately 3.9%[16] - Total liabilities rose to CNY 2,903,797,648.80 from CNY 2,638,233,049.69, an increase of about 10.1%[16] - The total equity attributable to shareholders decreased by 0.85% to ¥3,403,167,223.71 from the end of the previous year[4] - The company's equity attributable to shareholders decreased to CNY 3,403,167,223.71 from CNY 3,432,488,958.20, a decline of approximately 0.9%[16] Cash Flow - Cash flow from operating activities for the year-to-date was ¥301,778,903.76, down 22.11% compared to the same period last year[4] - Cash inflow from operating activities totaled 1,452,376,070.81 CNY, a decrease of 3.6% from 1,507,027,124.32 CNY in the previous year[20] - Net cash flow from operating activities was 301,778,903.76 CNY, down 22.1% from 387,422,308.32 CNY in the same period last year[20] - Cash inflow from financing activities was 1,321,773,872.14 CNY, an increase of 66.0% from 795,000,000.00 CNY in the previous year[21] - Net cash flow from financing activities increased by 199.04% to ¥175,390,506.38, primarily due to increased borrowings[8] - Cash outflow from investment activities was 336,024,266.17 CNY, compared to 387,541,864.51 CNY in the previous year[21] - Net cash flow from investment activities was -157,096,606.05 CNY, worsening from -71,638,260.24 CNY year-over-year[21] Investments and Subsidiaries - The company established a new subsidiary, New Xiangzhongxing Biotechnology Co., Ltd., with a total investment of CNY 10 million, focusing on the research and cultivation of rare edible (medicinal) fungi[12] - The company transferred its 55.17% stake in New Xiangzhongxing Biotechnology Co., Ltd. to New Xianghe, resulting in New Xianghe holding 100% of the subsidiary[12] - Investment income for the first nine months of 2024 decreased by 83.17% to ¥1,696,820.65 due to a reduction in maturing financial products[8] Shareholder Information - The total number of common shareholders at the end of the reporting period is 36,258[10] - The company has not reported any changes in the participation of major shareholders in margin trading and securities lending activities[10] Other Financial Metrics - The company's weighted average return on equity was 1.75%, a decrease of 2.39% compared to the previous year[4] - The company's fixed assets decreased to CNY 2,292,503,155.02 from CNY 2,439,717,475.88, a reduction of about 6.0%[13] - Non-current assets include long-term equity investments of CNY 47,249,032.15, up from CNY 19,818,894.03, indicating a significant increase of approximately 138.5%[13] - The fair value change income was CNY 4,987,945.18, contrasting with a loss of CNY 9,007,189.44 in the previous period[19] - The company reported a net loss from credit impairment of CNY 108,714.59, compared to a gain of CNY 745,099.55 in the previous period[19] Audit Status - The report for Q3 2024 was not audited[22]